Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trialPaolo A. Ascierto, James Larkin, Luis de la Cruz‐Merino et al.|The Lancet Oncology|2016Cited by 1k
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanomaBrigitte Dréno, Antoni Ribas, Isabelle Rooney et al.|British Journal of Cancer|2018Cited by 24
25LBA Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM studyGrant A. McArthur, A. Ribas, Isabelle Rooney et al.|European Journal of Cancer|2015Cited by 10